United Asset Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

United Asset Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.43M	Sell	2,882 -83	-3%	-$36.8K	0.1%	123
2026 Q1	$1.32M	Sell	2,965 -45	-1%	-$21K	0.11%	117
2025 Q4	$1.36M	Buy	3,010 +66	+2%	+$28.4K	0.11%	127
2025 Q3	$1.15M	Sell	2,944 -1,243	-30%	-$519K	0.09%	130
2025 Q2	$1.86M	Sell	4,187 -425	-9%	-$196K	0.16%	105
2025 Q1	$2.24M	Buy	4,612 +661	+17%	+$308K	0.21%	91
2024 Q4	$1.59M	Buy	3,951 +196	+5%	+$90.9K	0.15%	116
2024 Q3	$1.75M	Buy	3,755 +82	+2%	+$39.4K	0.16%	114
2024 Q2	$1.72M	Buy	3,673 +2,203	+150%	+$956K	0.17%	108
2024 Q1	$614K	Buy	+1,470	New	+$621K	0.06%	182

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

United Asset Strategies's VRTX Position: Q2 2026 in Review

United Asset Strategies reduced its Vertex Pharmaceuticals (VRTX) stake by 2.8% in Q2 2026, selling an estimated $36.8K and leaving 2,882 shares worth $1.43M. The position accounts for 0.1% of the portfolio, ranked #123.

United Asset Strategies first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.24M in Q1 2025. 484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

United Asset Strategies held 2,882 shares of Vertex Pharmaceuticals worth $1.43M as of Q2 2026.
United Asset Strategies sold 83 Vertex Pharmaceuticals shares in Q2 2026, an estimated $36.8K.
Vertex Pharmaceuticals made up 0.1% of United Asset Strategies's portfolio in Q2 2026, its #123 holding.
United Asset Strategies first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
United Asset Strategies's Vertex Pharmaceuticals position peaked at $2.24M in Q1 2025.
484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on United Asset Strategies's 13F filing for Q2 2026, filed 13 Jul 2026.